Jonathan Z. Li

Jonathan Z. Li

Auto-generated profile, based on publicly available information

Jonathan Z. Li

Brigham And Women’s Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JFJesse Fajnzylber
Jesse Fajnzylber
JRJames Regan
James Regan
KCKendyll Coxen
Kendyll Coxen
HCHeather Corry
Heather Corry
CWColline Wong
Colline Wong
JLJonathan Z. Li
Jonathan Z. Li
The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.

19 February 2021 in Science
Verified
Journal Article
Open access
PDF file
TSTyler N. Starr
Tyler N. Starr
AGAllison J. Greaney
Allison J. Greaney
AAAmin Addetia
Amin Addetia
WHWilliam W. Hannon
William W. Hannon
MCManish Chandra Choudhary
Manish Chandra Choudhary
JBJesse Bloom
Jesse Bloom
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850

6 April 2011 in JAMA
Verified
Journal Article
Closed access
PDF file
JLJonathan Z. Li
Jonathan Z. Li
RPRoger Paredes
Roger Paredes
HRHeather J. Ribaudo
Heather J. Ribaudo
ESEvguenia S. Svarovskaia
Evguenia S. Svarovskaia
KMKarin J. Metzner
Karin J. Metzner
DKDaniel R. Kuritzkes
Daniel R. Kuritzkes
ContextPresence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-1) drug resistance mutations may adversely affect response to antiretroviral treatment (ART), but evidence regarding the effects of such mutations on the effectiveness of first-line ART is conflicting.ObjectiveTo evaluate the association of preexisting drug-resistant HIV-1 minority variants with risk of first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)–based antiretroviral virologic failure.Data SourcesSystematic review of published and unpublished studies in PubMed (1966 through December 2010), EMBASE (1974 through December 2010), conference abstracts, and article references. Authors of all studies were contacted for detailed laboratory, ART, and adherence data.Study Selection and Data AbstractionStudies involving ART-naive participants initiating NNRTI-based regimens were included. Participants were included if all drugs in their ART regimen were fully active by standard HIV drug resistance testing. Cox proportional hazard models using pooled patient-level data were used to estimate the risk of virologic failure based on a Prentice weighted case-cohort analysis stratified by study.Data SynthesisIndividual data from 10 studies and 985 participants were available for the primary analysis. Low-frequency drug resistance mutations were detected in 187 participants, including 117 of 808 patients in the cohort studies. Low-frequency HIV-1 drug resistance mutations were associated with an increased risk of virologic failure (hazard ratio (HR], 2.3 [95% confidence interval {CI}, 1.7-3.3]; P < .001) after controlling for medication adherence, race/ethnicity, baseline CD4 cell count, and plasma HIV-1 RNA levels. Increased risk of virologic failure was most strongly associated with minority variants resistant to NNRTIs (HR, 2.6 [95% CI, 1.9-3.5]; P < .001). Among participants from the cohort studies, 35% of those with detectable minority variants experienced virologic failure compared with 15% of those without minority variants. The presence of minority variants was associated with 2.5 to 3 times the risk of virologic failure at either 95% or greater or less than 95% overall medication adherence. A dose-dependent increased risk of virologic failure was found in participants with a higher proportion or quantity of drug-resistant variants.ConclusionIn a pooled analysis, low-frequency HIV-1 drug resistance mutations, particularly involving NNRTI resistance, were significantly associated with a dose-dependent increased risk of virologic failure with first-line ART.

1 November 2015 in AIDS
Verified
Journal Article
Closed access
JLJonathan Z. Li
Jonathan Z. Li
BEBehzad Etemad
Behzad Etemad
HAHayat Ahmed
Hayat Ahmed
EAEvgenia Aga
Evgenia Aga
RBRonald J. Bosch
Ronald J. Bosch
RGRajesh T. Gandhi
Rajesh T. Gandhi
Therapies to achieve sustained antiretroviral therapy-free HIV remission will require validation in analytic treatment interruption (ATI) trials. Identifying biomarkers that predict time to viral rebound could accelerate the development of such therapeutics. A pooled analysis of participants from six AIDS Clinical Trials Group ATI studies to identify predictors of viral rebound. Cell-associated DNA (CA-DNA) and CA-RNA were quantified in pre-ATI peripheral blood mononuclear cell samples, and residual plasma viremia was measured using the single-copy assay. Participants who initiated antiretroviral therapy (ART) during acute/early HIV infection and those on a non-nucleoside reverse transcriptase inhibitor-containing regimen had significantly delayed viral rebound. Participants who initiated ART during acute/early infection had lower levels of pre-ATI CA-RNA (acute/early vs. chronic-treated: median <92 vs. 156 HIV-1 RNA copies/10 CD4 cells, P < 0.01). Higher pre-ATI CA-RNA levels were significantly associated with shorter time to viral rebound (≤4 vs. 5-8 vs. >8 weeks: median 182 vs. 107 vs. <92 HIV-1 RNA copies/10 CD4 cells, Kruskal-Wallis P < 0.01). The proportion of participants with detectable plasma residual viremia prior to ATI was significantly higher among those with shorter time to viral rebound. Higher levels of HIV expression while on ART are associated with shorter time to HIV rebound after treatment interruption. Quantification of the active HIV reservoir may provide a biomarker of efficacy for therapies that aim to achieve ART-free HIV remission.

8 August 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
DNDevora Najjar
Devora Najjar
JRJoshua Rainbow
Joshua Rainbow
STSanjay Sharma Timilsina
Sanjay Sharma Timilsina
PJPawan Jolly
Pawan Jolly
HPHelena de Puig
Helena de Puig
DIDonald E Ingber
Donald E Ingber

6 August 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
GNGolnaz Namazi
Golnaz Namazi
JFJesse M Fajnzylber
Jesse M Fajnzylber
EAEvgenia Aga
Evgenia Aga
RBRonald J Bosch
Ronald J Bosch
EAEdward P Acosta
Edward P Acosta
JLJonathan Z Li
Jonathan Z Li
HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were compared between posttreatment controllers and noncontrollers. Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission.